544 results on '"Jäger U"'
Search Results
2. Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas
3. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)
4. Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials
5. Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group
6. A Comprehensive Analysis of the Cellular and EBV-Specific MicroRNAome in Primary CNS PTLD Identifies Different Patterns Among EBV-Associated Tumors
7. Lupus anticoagulant and thrombosis in splenic marginal zone lymphoma
8. Impact of gender on outcome after chemoimmunotherapy in patients with chronic lymphocytic leukemia: a meta-analysis by the German CLL study group
9. Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1 and MYC, and can be targeted by SYK inhibition
10. Alemtuzumab-BEAM as conditioning for allogeneic hematopoietic stem cell transplantation in relapsed/refractory Hodgkin lymphoma: a single-center analysis
11. Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
12. Rapid decline in insulin antibodies and glutamic acid decarboxylase autoantibodies with ibrutinib therapy of chronic lymphocytic leukaemia
13. Molecular classification of tumour cells in a patient with intravascular large B‐cell lymphoma
14. Challenge of design for the Westerschelde tunnel in the Netherlands
15. Characterization of height-selective emitters
16. Management of adults and children receiving CAR T- cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)
17. Impedance platelet aggregometry for surveillance of ibrutinib therapy in chronic lymphocytic leukaemia: 151
18. High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS)
19. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
20. Sequential gene expression profiling during treatment for identification of predictive markers and novel therapeutic targets in chronic lymphocytic leukemia
21. Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma
22. Expression of MUM1/IRF4 mRNA as a prognostic marker in patients with multiple myeloma
23. Clinical and prognostic significance of histamine monitoring in patients with CML during treatment with imatinib (STI571)
24. Deregulated expression of fat and muscle genes in B-cell chronic lymphocytic leukemia with high lipoprotein lipase expression
25. Influence of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone on serologic parameters and clinical course in lymphoma patients with autoimmune diseases
26. Phenotyping and Target Expression Profiling of CD34+/CD38− and CD34+/CD38+ Stem- and Progenitor cells in Acute Lymphoblastic Leukemia
27. Remission of pure red cell aplasia in T-cell receptor γδ-large granular lymphocyte leukemia after therapy with low-dose alemtuzumab
28. High expression of lipoprotein lipase in poor risk B-cell chronic lymphocytic leukemia
29. Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma
30. RT-PCR and FISH analysis of acute myeloid leukemia with t(8;16)(p11;p13) and chimeric MOZ and CBP transcripts: breakpoint cluster region and clinical implications
31. High expression of activation-induced cytidine deaminase (AID) mRNA is associated with unmutated IGVH gene status and unfavourable cytogenetic aberrations in patients with chronic lymphocytic leukaemia
32. Impact of cytogenetics on the prognosis of adults with de novo AML in first relapse
33. Fibrinolytic therapy with rt-PA in a patient with paroxysmal nocturnal hemoglobinuria and Budd-Chiari syndrome
34. Association of mean platelet volume with cancer-associated venous thromboembolism: results from the vienna cancer and thrombosis study (CATS): OC 31.1
35. A comparative study on demographic, hematological, and cytogenetic findings and prognosis in acute myeloid leukemia with and without leukemia cutis
36. CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells
37. Treatment of leukemic relapse after allogeneic stem cell transplantation with cytotoreductive chemotherapy and/or immunotherapy or second transplants
38. Deletions of chromosome 13q in monoclonal gammopathy of undetermined significance
39. Fludarabine therapy in Waldenström's macroglobulinemia
40. Excellent disease eradication by myeloablative therapy and stem-cell transplantation in patients with acute myelogenous leukemia
41. Generation of a high titre retroviral vector for endothelial cell-specific gene expression in vivo
42. Drug resistance factors in acute myeloid leukemia: a comparative analysis
43. The cytomegalovirus protein pUL32 is highly conserved among clinical strains although a major target of the humoral and cellular immune response: O394
44. Granulocyte colony-stimulating factor-supported combined immunosuppressive therapy (antilymphocyte globulin, cyclosporine, and methylprednisolone) in patients with aplastic anemia: tolerability, efficacy, and changes in the progenitor cell compartment
45. Induction of complement attack on human cells by Gal(alpha1,3)Gal xenoantigen expression as a gene therapy approach to cancer
46. Impact of TP53 Mutations on Outcome: Results from the CLL8 Trial (FC vs. R-FC) of the GCLLSG: V87
47. Stable non-transforming minimal residual disease (MRD) in Ph+ ALL after autologous stem cell transplantation: origin from neoplastic pre-leukemic stem cells?: 014
48. Methotrexate-induced primary cutaneous diffuse large B-cell lymphoma with an ‘angiocentric’ histological morphology
49. Detection of the WT1 transcript by RT-PCR in complete remission has no prognostic relevance in de novo acute myeloid leukemia
50. Hypofibrinogenemia in non-M3 acute myeloid leukemia. Incidence, clinical and laboratory characteristics and prognosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.